Table 2 Summary: within patient change for CCP+ status to VERA (progression) in both phases and CCP+ status to non-progression within patient change and vs. progressors from the validation phase
From: Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis
CCP+ to VERA | CCP+ to no progression | CCP+ non progressor | CCP+ progressor | Progressors vs. non progressors | ||||
|---|---|---|---|---|---|---|---|---|
Median FC (IQR 1st, 3rd) | Median FC (IQR 1st, 3rd) | B/L median dCt (IQR) | B/L median dCt (IQR) | FD between medians | Area under ROC curve (90% CI) | Sens | Spec | |
Pilot phase | ||||||||
miR-22 | 4.3 (2.8, 12.1) | - | - | - | - | - | - | |
miR-382 | 4.1 (1.7, 6.9) | - | - | - | ||||
miR-486-3p | 4.1 (0.9, 8.6) | - | - | - | - | - | - | |
Validation Phase | ||||||||
miR-22 | 2.5 (-2.2, 15.3) | 3.4 (2.3, 12.6) | 7.4 (4.1, 8.2) | 3.1 (1.8, 7.3) | 19.7 | 0.68 (0.48, 0.82) | 63% | 100% |
miR-382 | 1.2 (-2.1, 2.7) | 2.4 (1.0, 2.6) | 1.1 (0.0, 1.8) | -0.2 (-0.5, 1.9) | 2.5 | 0.57 (0.40, 0.75) | 75% | 58% |
miR-486-3p | 2.2 (-2.5, 6.0) | 1.0 (-1.4, 3.0) | 3.4 (1.7, 3.9) | 3.9 (2.6, 5.0) | -1.4 | 0.55 (0.36, 0.72) | 50% | 75% |